Fig. 1: PMM2 knockdown inhibits malignant phenotypes of CRC cells. | Oncogene

Fig. 1: PMM2 knockdown inhibits malignant phenotypes of CRC cells.

From: PMM2 interacts with TRIM28 to recruit E2F4 and promote KIFC3-mediated tumor glycolysis and colorectal cancer progression

Fig. 1: PMM2 knockdown inhibits malignant phenotypes of CRC cells.

A Volcano plot showing differentially expressed genes in CRC tissues vs. matched normal tissues (|log2FC|>1, FDR < 0.05). PMM2 is highlighted as a top upregulated gene. B Proliferation of RKO cells transfected with shRNAs targeting indicated genes or control shRNA (shCtrl), measured by CCK-8 assay. C RT-qPCR analysis of PMM2 mRNA levels in CRC cell lines (RKO, HT-29, HCT-116, Caco-2, HT-15) and normal rectal epithelial cell line NCM460. D Proliferation of HCT-116 cells with PMM2 knockdown using PMM2 shRNA-1 (shPMM2-1) and shRNA-2 (shPMM2-2), assessed by CCK-8 assay. E Colony formation assay in HCT-116 cells with PMM2 knockdown. F Flow cytometry analysis of apoptosis in HCT-116 cells with PMM2 knockdown. G Wound healing assay showing migration of HCT-116 cells with PMM2 knockdown. H Transwell invasion assay in HCT-116 cells with PMM2 knockdown. Data are mean ± SD (n = 3). *p < 0.05, **p < 0.01 vs. shCtrl.

Back to article page